An authoritative database of FDA’s fast-tracked medical devices. STAT Reports blend data insights with qualitative observations on pivotal life sciences topics.

At STAT, our mission is to deliver trusted, tough-minded journalism on the business of making medicines, health tech, science, public health, hospitals, and insurance.

Health STAT Staff Best of STAT 2025 Health Helen Branswell 3 issues to watch in public health in 2026 First Opinion Sara Rubinelli, Rebecca Ivic, Kenneth H. Rabin, Lawrence O. Gostin, and Scott C ...

CDC approves new hepatitis B vaccine recommendation as some hospitals reject changes D.C. Diagnosis STAT Staff and John Wilkerson House juggles options for extending ACA subsidies Next …

Our price covers the cost of daily coverage, two daily STAT+ newsletters, free access to exclusive subscriber only virtual events, discounts to STAT events and summits, and additional benefits.

STAT’s annual Monday evening event at JPM examines the political, social, and scientific forces reshaping health care in the year ahead.

STAT coverage and analysis of top pharmaceutical companies, from clinical trials to FDA approvals, from startups to Big Pharma mergers and acquisitions.

Each spring, STAT’s editorial team brings together leaders advancing science and medicine in New York City. Planning for Breakthrough East 2026 is underway. Check back soon for updates

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Learn More. Cancel anytime. Interested in a group rate? Contact us.

Curious to see what our recent summits were like? Check out our last summit, 2025 STAT Summit, to see featured speakers, session information, and coverage highlights.